Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00415571 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Evaluating Fispemifene in the Treatment of Hypogonadal Men With Erectile Dysfunction Unresponsive to PDE5 Inhibitors
A Phase 2 study, sponsored by QuatRx Pharmaceuticals Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT00415571 is a Phase 2 study that has completed, run by QuatRx Pharmaceuticals Company. The registered enrollment target is 72 participants.
The verdict
NCT00415571, a Phase 2 study, has completed, sponsored by QuatRx Pharmaceuticals Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
The objective of the study is to assess and compare the preliminary efficacy, safety and tolerability of fispemifene 300 mg and placebo given once daily for 8 weeks in the treatment of hypogonadal men with erectile dysfunction (ED) unresponsive to PDE5 inhibitors.
Interventions
- DRUG Fispemifene (once daily for 8 weeks)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2006-12 |
| Est. Completion | 2008-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00415571
The ClinicalTrials.gov registry entry for NCT00415571 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is QuatRx Pharmaceuticals Company, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fispemifene (once daily for 8 weeks) is the first listed.
NCT00415571 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00415571 about?
NCT00415571 is a clinical study titled "Efficacy and Safety Evaluating Fispemifene in the Treatment of Hypogonadal Men With Erectile Dysfunction Unresponsive to PDE5 Inhibitors". The objective of the study is to assess and compare the preliminary efficacy, safety and tolerability of fispemifene 300 mg and placebo given once daily for 8 weeks in the treatment of hypogonadal men with erectile dysfunction (ED) unresponsive to PDE5 inhibitors.
What is the current status of trial NCT00415571?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2006-12. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00415571?
The interventions under investigation include: Fispemifene (once daily for 8 weeks) (DRUG).
Who is sponsoring clinical trial NCT00415571?
This trial is sponsored by QuatRx Pharmaceuticals Company, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.